MX9702524A - Virus atenuados y metodo para elaborarlos. - Google Patents

Virus atenuados y metodo para elaborarlos.

Info

Publication number
MX9702524A
MX9702524A MX9702524A MX9702524A MX9702524A MX 9702524 A MX9702524 A MX 9702524A MX 9702524 A MX9702524 A MX 9702524A MX 9702524 A MX9702524 A MX 9702524A MX 9702524 A MX9702524 A MX 9702524A
Authority
MX
Mexico
Prior art keywords
attenuated viruses
genome
making
virus
same
Prior art date
Application number
MX9702524A
Other languages
English (en)
Other versions
MXPA97002524A (es
Inventor
Jonathan W Nyce
Original Assignee
Univ East Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ East Carolina filed Critical Univ East Carolina
Publication of MXPA97002524A publication Critical patent/MXPA97002524A/es
Publication of MX9702524A publication Critical patent/MX9702524A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen virus atenuados, que no ocurren naturalmente, que contienen uno o más sitios de metilacion adicionales en el genoma del virus, en comparacion con el virus tipo silvestre correspondiente. De preferencia los sitios de metilacion son agregados en el genoma del virus introduciendo un segmento CG adicional en el genoma por medio de una mutilacion silent. Los virus atenuados son utiles para producir una respuesta inmune, incluyendo tanto la produccion de anticuerpos en animales para uso de diagnostico como para la induccion de inmunidad protectora en un sujeto. También se describen formulaciones farmacéuticas y métodos para elaborar los virus atenuados.
MX9702524A 1994-10-07 1995-10-05 Virus atenuados y metodo para elaborarlos. MX9702524A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08319974 1994-10-07
US08/319,974 US20030104576A1 (en) 1994-10-07 1994-10-07 Dna construct, composition, formulations & methods for making the construct & for modulating expression
PCT/US1995/013219 WO1996011280A1 (en) 1994-10-07 1995-10-05 Attenuated viruses and method of making the same

Publications (2)

Publication Number Publication Date
MXPA97002524A MXPA97002524A (es) 1998-02-01
MX9702524A true MX9702524A (es) 1998-02-28

Family

ID=23244339

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702524A MX9702524A (es) 1994-10-07 1995-10-05 Virus atenuados y metodo para elaborarlos.

Country Status (10)

Country Link
US (1) US20030104576A1 (es)
EP (1) EP0784692A1 (es)
JP (1) JPH10507077A (es)
KR (1) KR970706399A (es)
CN (1) CN1169161A (es)
CA (1) CA2201487A1 (es)
MX (1) MX9702524A (es)
NO (1) NO971495L (es)
NZ (1) NZ295070A (es)
WO (1) WO1996011280A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
ES2322172T3 (es) * 2004-05-26 2009-06-17 Biovaxim Limited Composiciones que comprenden agentes desmetilantes como potenciadores de la inmunoterapia para el tratamiento de infecciones cronicas y enfermedades neoplasicas y metodos para tratar las mismas.
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN101045946B (zh) * 2007-04-29 2010-09-29 深圳市疾病预防控制中心 Hiv基因检测芯片及其制备方法
AR063866A1 (es) * 2007-11-20 2009-02-25 Consejo Nac Invest Cient Tec Un procedimiento para la obtencion de cepas virales atenuadas
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CN103501811B (zh) * 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
AU2012302051B2 (en) 2011-08-30 2017-04-27 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
ES2784351T3 (es) * 2015-05-18 2020-09-24 Calimmune Inc Métodos de discriminación entre el VIH-1 y vectores de lentivíricos
RU2723590C2 (ru) 2015-07-02 2020-06-16 Оцука Фармасьютикал Ко., Лтд. Лиофилизированные фармацевтические композиции
AU2018310857A1 (en) 2017-08-03 2020-02-13 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
CN113186353A (zh) * 2021-05-28 2021-07-30 杭州晶佰生物技术有限公司 针对c型逆转录病毒的数字pcr检测用引物及检测方法

Also Published As

Publication number Publication date
EP0784692A1 (en) 1997-07-23
CA2201487A1 (en) 1996-04-18
WO1996011280A1 (en) 1996-04-18
KR970706399A (ko) 1997-11-03
AU3832795A (en) 1996-05-02
CN1169161A (zh) 1997-12-31
NO971495L (no) 1997-05-26
AU707782B2 (en) 1999-07-22
US20030104576A1 (en) 2003-06-05
NZ295070A (en) 1999-11-29
JPH10507077A (ja) 1998-07-14
NO971495D0 (no) 1997-04-02

Similar Documents

Publication Publication Date Title
MX9702524A (es) Virus atenuados y metodo para elaborarlos.
EP0835133A4 (en) RECOMBINANT COMPOSITIONS AND COMBINED COMPOSITIONS OF RABIES AND SMALLPOX VIRUSES, AND USES THEREOF
ATE454163T1 (de) Bakterielle impfstoffe, enthaltend auxotrophe attenuierte listerienstämme, welche heterologe antigene exprimieren
HU9302575D0 (en) Dendritical macromolecules and process for preparation thereof
ES8203226A1 (es) Procedimiento de preparar complejos vacunantes por reaccion de arn ribonosales y de antigenos especificos.
ES8801319A1 (es) Un metodo para la deteccion de anticuerpos especificos de un virus lav en un fluido biologico.
TR200202448T2 (tr) Genetik olarak oluşturulmuş uçuk aşısı
HUT38841A (en) Process for producing compositions for producing immune-response against tumours and virus
FI964592A (fi) Papilloomavirusrokotteita
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
ES8505719A1 (es) Procedimiento de preparar mutantes de delecion vivos y metodo de preparar vacunas
CA2094515A1 (en) Bacterial Attenuation Method and Vaccine
ATE219511T1 (de) Streptococcus equi impstoff
CA2185470A1 (en) Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
DK0478602T3 (da) Ekspression af tetanus toxin fragment C
AU2002217043A1 (en) Salmonella vaccine
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
EP0868522A4 (en) RECOMBINANT POX VIRUS OF INFECTIOUS PERITONITIS OF THE CAT, COMPOSITIONS THEREOF AND METHODS FOR THE PRODUCTION AND USE
DK0892054T3 (da) Clostridium perfringens-vaccine
NZ238833A (en) Equine herpesvirus-4 gh or gc polypeptides, nucleic acids encoding them and vaccines therefrom
EP0127153A3 (en) Bivalent vaccines
TW200502384A (en) Live attenuated bacteria of the species actinobacillus pleuropneumoniae
ES8105930A1 (es) Procedimiento para la preparacion de vacunas de virus poli- valentes
GB9726233D0 (en) Vaccines containing attenuated bacteria